PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse by Hiroaki Konishi et al.
Konishi et al. BMC Cancer 2012, 12:462
http://www.biomedcentral.com/1471-2407/12/462RESEARCH ARTICLE Open AccessPEGylated liposome IHL-305 markedly improved
the survival of ovarian cancer peritoneal
metastasis in mouse
Hiroaki Konishi, Akimitsu Takagi*, Akinobu Kurita, Norimasa Kaneda and Takeshi MatsuzakiAbstract
Background: Advanced ovarian cancer is characterized by peritoneal metastasis and the accumulation of ascites.
Peritoneal metastasis of ovarian cancer is a major cause of the negative treatment outcome, as these metastases
are resistant to most chemotherapy regimens. The aim of this study was to clarify aggressive pathology of
peritoneal metastasis and examine the therapeutic efficacy of a liposomal agent in the model.
Methods: A human cancer cell line ES-2 of ovarian clear cell carcinoma, known as a chemotherapy-resistant cancer,
was cultured in nonadherent plate to form spheroid and single cell suspension was transplanted into mouse
peritoneal cavity. The epidermal growth factor receptor (EGFR) pathways in the cellular aggregates were analyzed
both spheroid and ascites. The pharmacokinetics and therapeutic efficacy of CPT-11 (45 mg/kg) and IHL-305
(45 mg/kg), an irinotecan-encapsulated liposome, were examined by intravenous administration.
Results: Established peritoneal metastasis model showed an accumulation of ascites. The activation of EGFR and
Akt was demonstrated in cellular aggregates both in the spheroid and ascites. In ascites samples, the area under
the curve of SN-38, the activated form of CPT-11, was 3.8 times higher from IHL-305-treated mice than from
CPT-11-treated mice. IHL-305 prolonged the survival time and decreased the accumulation of ascites and tumor
metastasis. The median survival time were 22, 37 and 54 days in the control, CPT-11-treated, and IHL-305-treated
mice, respectively.
Conclusions: EGFR/Akt pathway contributes to the aggressive progression in ES-2 peritoneal metastasis model and
effective delivery into ascites of IHL-305 was thought to useful treatment for ovarian cancer with peritoneal
metastasis.
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About 14,000 people die from ovarian cancer every year
in the United States [1]. The five-year survival rate of
patients with ovarian cancer is lower than that for other
gynecologic cancers. Unlike other cancers, ovarian can-
cer cells spread widely throughout the peritoneal cavity
because of the absence of an anatomical barrier. The
relatively poor prognosis for patients with ovarian cancer
is due to a frequently advanced disease stage with peri-
toneal metastasis at the time of diagnosis [2], and a sub-
stantially lower survival rate for advanced stages than for* Correspondence: akimitsu-takagi@yakult.co.jp
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reproduction in any medium, provided the orearly stages [3]. To improve the survival rate of patients
with ovarian cancer, many efforts have been made to de-
tect ovarian cancer at an early stage before peritoneal
metastasis had occurred.
CA-125 is used as a tumor marker to detect ovarian
cancer, but it is not a reliable marker for early-stage dis-
ease [4]. In addition, the subjective symptoms are impre-
cise [2]. Currently, the detection of early-stage ovarian
cancer is extremely difficult. For the treatment of ovar-
ian cancer with peritoneal metastasis, the intraperitoneal
administration of cisplatin or paclitaxel has been exam-
ined in clinical trials. Though some of these trials were
successful [3,5-7], other trials did not succeed because of
chemical peritonitis and the enhancement of adverseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Relation between the number of inoculated ES-2 cells
and the survival of the inoculated mice. Various numbers of ES-2
human ovarian cancer cells (2 × 104 cells (●), 2 × 105 cells (▲), 2 × 106
cells (■), 2 × 107 cells (♦)) were inoculated into the peritoneal cavity of
mice. After inoculation, the survival time of the mice was examined
(n=5, each group).
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tion has been shown to have a minimal effect [9]. None
of the intraperitoneal or intravenous chemotherapy regi-
mens have been confirmed as effective against ovarian
cancer with peritoneal metastasis. Thus, a novel therapy
for the treatment of ovarian cancer with peritoneal me-
tastasis is needed.
Some experimental studies have been conducted to
characterize the mechanism of peritoneal metastasis.
Heparin-binding EGF-like growth factor (HB-EGF), stro-
mal cell-derived factor 1alpha (SDF-1α)/CXC receptor 4
and vascular cell adhesion molecule-1 (VCAM-1) have
been reported to be related to the progression of peri-
toneal metastasis in ex vivo studies [10-12], and the acti-
vation of HER2, a member of the epidermal growth
factor receptor (EGFR) family, has been reported in
spheroid cultures [13]. The activation of EGFR pathways
has been shown to be involved in tumorigenesis in many
cancers [14]. Spheroid cultures are regarded as a suitable
in vitro model of peritoneal metastasis especially with
regard to their anchorage-independent growth, which
resembles floating cancer cell aggregates in ascites; how-
ever, the EGFR pathways in spheroid cultures are not
fully understood.
In peritoneal metastasis, it is difficult to resect cancer
cells completely because the cells spread throughout the
peritoneal cavity. Consequently, the delivery and mainten-
ance of anti-cancer agents in the peritoneal cavity is an
important therapeutic strategy. Liposome delivery has
been demonstrated to improve the pharmacokinetic pro-
file and therapeutic efficacy of various anti-cancer agents
[15,16]. Improved efficacy is in part a result of the passive
targeting of tumor sites based on the enhanced permeabil-
ity and retention (EPR) effect. Liposomes are captured by
the reticuloendothelial system (RES); however, liposomes
with surfaces that have been modified with polyethylene
glycol (PEG) are able to avoid uptake by the RES and have
a longer retention time in the blood [17]. Irinotecan
hydrochloride (CPT-11), which acts by inhibiting DNA
topoisomerase I, is widely used against colorectal and
ovarian cancer because of its robust efficacy [18,19]. IHL-
305 has developed as an irinotecan-encapsulated and
PEGylated liposome, and its antitumor-activity have been
demonstrated in mouse model [20]. Efficient delivery of
PEGylated liposome encapsulated with vinorelbine and
doxorubicin into ascites fluid have been reported [21,22].
Thus, we hypothesized that liposomal formulations of
anti-cancer agents might be useful for the treatment of
peritoneal metastasis.
In this study, a murine model for the peritoneal metasta-
sis of ovarian cancer was established using a human clear
cancer cell line. This model was accompanied by accumu-
lation of ascites, and EGFR pathways were activated in cel-
lular aggregates collected from the ascites. Intravenouslyadministrated IHL-305 was efficiently delivered into peri-
toneal ascites; this drug delivery system prolonged the sur-
vival of the mouse with peritoneal metastasis.Results
Establishment of ES-2 peritoneal metastasis mouse model
Various numbers of ES-2 human ovarian cancer cells
were inoculated into the peritoneal cavities of mice, and
the survival and performance statuses after inoculation
were observed. The survival time decreased depending
on the number of inoculated cells (Figure 1). The accu-
mulation of ascites and the formation of metastatic
tumor nodules surrounding organs in the peritoneal cav-
ity were observed after the inoculation of 2 × 104 to 106
ES-2 cells. Floating cell aggregates were also observed in
the ascites. Mice inoculated with 2 × 107 ES-2 cells had
the shortest survival period and did not exhibit the accu-
mulation of ascites. The optimal number of inoculated
cells was decided to be 2 × 105 cells because mice inocu-
lated with this number of cells exhibited characteristics
of peritoneal metastasis such as the accumulation of as-
cites and the formation of metastases.
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and in ascites in vivo
Tumor cell aggregates that were detached and floating
in ascites were observed in the mouse models. When
attached cells lose their anchorage, a form of cell death
known as anoikis is induced. Spheroids are regarded as
an anchorage-independent growth experimental model,
and the involvement of Akt has been reported in anoikis
resistance [23]. In ES-2 spheroids, the phosphorylation
of Akt was detected, and the phosphorylation of EGFR
and ERK1/2, an EGFR downstream molecule involved in
a pathway other than the one involving Akt, also
detected (Figure 2A). However, the phosphorylation of
ERK1/2 was transiently down-regulated in the process of
growth. Likewise, the phosphorylation of both EGFR
and Akt and ERK1/2 were observed in cancer cell aggre-
gates in ascites (Figure 2B). Thus, EGFR and its down-
stream signals were clearly up-regulated in the ES-2
cancer cell-induced peritoneal metastasis models both
in vitro and in vivo.
Cytotoxic activity of anti-cancer agents against ES-2
monolayer and spheroids
The cytotoxic activity of anti-cancer agents against ES-2
monolayer and spheroids, an in vitro model of peritoneal
metastasis, was compared using cisplatin (a platinum
drug, CDDP), paclitaxel (a tubulin inhibitor, PTX), SN-
38 (a topoisomerase I inhibitor, an active metabolite of
CPT-11), and PD153035 (an EGFR inhibitor). CDDP,
PTX and CPT-11 are clinically used against ovarianFigure 2 Activation of EGFR pathways in both in vitro and in vivo mo
molecules (EGFR, Akt and ERK) were examined in ES-2 cells in spheroid cul
status was examined to evaluate the activated forms of these proteins. The
Ser473 and Thr202/Tyr204, respectively. (A) ES-2 cells were seeded into a sphe
monolayer culture. (B) ES-2 cell aggregates in ascites were collected from mcancers [24]. In general, the activities of the anti-cancer
agents were reduced in the spheroids [25]. The IC50
values of CDDP, PTX, SN-38 and PD153035 in mono-
layer were 5.2 μM, <0.01 μM, <0.01 μM, 6.0 μM, re-
spectively (Figure 3A). The IC50 values of CDDP and
PTX in spheroids could not be estimated because of
their weak activities (Figure 3B). On the other hand, the
IC50 values of SN-38 and PD153035 in spheroids were
5.2 μM and 50 μM, respectively. Among the four agents
that were assayed, SN-38 exerted a relatively strong
cytotoxicity.
Pharmacokinetic profiles of CPT-11 and IHL-305
The metabolic conversion from CPT-11 to SN-38 by
esterase is necessary for the anti-cancer activity of CPT-
11. For the treatment of peritoneal metastasis, the deliv-
ery of anti-cancer agents to detached and floating cancer
cells in ascites is vital for therapy. The pharmacokinetic
profiles of CPT-11 and its liposomal formulation, IHL-
305, were examined in blood and ascites samples col-
lected from mice with peritoneal metastasis to determine
whether CPT-11, once released from IHL-305, is deliv-
ered to the ascites and converted to SN-38 and then to
SN-38 glucuronide (SN-38G) within the ascites. For this
purpose, the total amount of CPT-11 (tCPT-11), the
amount of CPT-11 that is released from IHL-305 (rCPT-
11), and the amounts of SN-38 and SN-38G were
determined using HPLC. The results indicated that the
pharmacokinetic profile of CPT-11 and its metabolites
were improved by the liposomal formulation. In thedels of peritoneal metastasis. The statuses of EGFR signaling
tures and in ascites using an immunoblotting analysis. Phosphorylation
analyzed sites of phosphorylation on EGFR, Akt and ERK were Tyr1069,
roid culture plate on day 1 and were analyzed on days 4 and 7. Ctrl:
ice with peritoneal metastasis (n=6, mouse ID#1-6).
Figure 3 Cytotoxicity of anti-cancer agents against ES-2 cell monolayers and spheroids. ES-2 cell monolayers (A) and spheroids (B) were
exposed to cisplatin (●), paclitaxel (▲), SN-38 (■) and PD153035 (♦) for 48 hr. The cytotoxic activity was measured using an MTS assay (n=3 per
group calculated from 3 independent experiments). The percentage of viable cells is shown relative to untreated controls.
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SN-38 and SN-38G rapidly decreased after administra-
tion in CPT-11-treated mice. In the IHL-305-treated
mice, however, the concentrations decreased slowly after
administration (Figure 4A). The AUC of SN-38 in the
IHL-305-treated mice was 2.8 times higher than that inFigure 4 Pharmacokinetic profile of IHL-305 in an ES-2 peritoneal me
○) was intravenously administered at 0 time to mice with peritoneal meta
from the liposome (rCPT-11), SN-38 and SN-38 glucuronide (SN-38G) werethe CPT-11-treated mice. In ascites samples, the concen-
trations of tCPT-11, rCPT-11, SN-38 and SN-38G
rapidly decreased just after administration in the CPT-
11-treated mice. In the IHL-305-treated mice, however,
the concentrations reached a maximum at 24 hr after
administration and then slowly decreased (Figure 4B).tastasis mouse model. CPT-11 (45 mg/kg: ●) or IHL-305 (45 mg/kg:
stasis. The concentrations of total CPT-11 (tCPT-11), released CPT-11
determined in (A) blood and (B) ascites.
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times higher than that in the CPT-11-treated mice.
Metastatic behaviors of peritoneal metastasis in mice
treated with CPT-11 or IHL-305
The typical metastatic behaviors observed in mice with
peritoneal metastasis are the accumulation of ascites and
metastasis to intra-abdominal organs, such as the omen-
tum and mesenterium. As surrogate endpoints of the
anti-cancer activity of CPT-11 and IHL-305, ascites and
metastasis parameters were examined after the adminis-
tration of these agents. CPT-11 showed an anti-cancer
activity, and IHL-305 showed an even greater activity.
Control mice exhibited high incidences of the accumula-
tion of ascites and the formation of metastases on days
18 and 26, and all the mice had died by day 31 after can-
cer cell inoculation. The CPT-11-treated mice exhibited
no accumulation of ascites on days 18 and 26, but high
incidences of metastasis were observed on days 18, 26
and 31. The IHL-305-treated mice exhibited no ascites
or metastasis on days 18, 26 and 31 except for one
mouse who exhibited a metastatic tumor on day 18
(Table 1). The anti-cancer potency of IHL-305 was thus
revealed by the strong suppression of the accumulation
of ascites and metastasis.
Survival of mice with peritoneal metastasis treated with
CPT-11, IHL-305
We demonstrated that CPT-11 and IHL-305 suppressed
the accumulation of ascites and the formation of metas-
tases as surrogate endpoints and examined the survival
time of the mice as the primary endpoint. The median
survival time (MST) after the inoculation of ES-2 cells
was 22, 37 and 54 days in the control, CPT-11-treated
and IHL-305-treated groups, respectively (Figure 5A).
Both CPT-11 and IHL-305 prolonged the survival time,Table 1 Abnormal ascites and tumor metastasis in peritoneal
Group Ascites
Incidence Volume (mL) O
Control 7/7 2.63±0.75
Day 18 CPT-11 0/5* -
IHL-305 0/5* -
Control 2/3 2.95±0.92
Day 26 CPT-11 0/4** -
IHL-305 0/5* -
Control - -
Day 31 CPT-11 3/4 0.68±0.89
IHL-305 0/5*** -
* p<0.01 vs. Ctrl.
** p<0.05 vs. Ctrl.
*** p<0.05 vs. CPT-11.
Analyzed by Kaplan-Meier method.compared with that in the control group (CPT-11,
p<0.01; IHL-305, p<0.01). IHL-305 significantly pro-
longed the survival time, compared with CPT-11
(p<0.01).
Schedule-independency of IHL-305 therapy
Finally, we examined the schedule-dependency of IHL-
305 on the therapeutic effect, since the efficacy of the
test compound against the aggressive progression of
peritoneal metastasis depends on the administration
schedule [26]. After the inoculation of ES-2 cells in mice
(day 1), IHL-305 was administered to mice according to
various schedules as follow: days 4, 8 and 12 (schedule
A), days 8, 12 and 16 (schedule B), and days 12, 16 and
20 (schedule C). The survival time was shortened in the
schedule C treatment group, but the difference was not
significant. The MST was 61, 50 and 49 days for the
schedule A, B and C groups, respectively (Figure 5B).
Thus, the survival time of the IHL-305-treated mice was
prolonged independently of the administration schedule.
Discussion
We examined the peritoneal metastasis of ovarian can-
cer using both in vitro and in vivo models in this experi-
mental study. We demonstrated that the accumulation
of ascites and a reduction in survival were induced by
the inoculation of the ES-2 ovarian clear cell carcinoma
cell line, a known chemotherapy-resistant cancer cell
type, into the peritoneal cavity and that the EGFR path-
ways were activated in the cancer cells in both the
in vitro and in vivo models. Since ES-2 cells harbor a
genetic mutation in B-raf, a downstream member of the
EGFR pathway and a known resistance factor against
anti-EGFR therapy [27], EGFR interference was thought
to be an unfavorable strategy in ES-2 models. Thus, we
focused on the management of ascites using a modifiedmetastasis mice
Metastasis (incidence)
mentum Diaphragm Mesenterium Pancreas
3/7 3/7 4/7 4/7
3/5 0/5 4/5 0/5
1/5 0/5 1/5 0/5
3/3 3/3 3/3 2/3
3/4 3/4 4/4 1/4
0/5 0/5 0/5 0/5
- - - -
4/4 3/4 4/4 2/4
0/5 0/5 0/5 0/5
Figure 5 Survival time of the ES-2 peritoneal metastasis mouse model after treatment with CPT-11 or IHL-305. ES-2 cells (2 x 105 cells)
were inoculated into the peritoneal cavity of mice on day 1. (A) Saline as the vehicle control (●), CPT-11 (45 mg/kg/day:▲) or IHL-305 (45 mg/
kg/day: ■) was administered on days 4, 8, and 12, and the survival time was analyzed (n=10, each group). (B) Saline was administered as the
vehicle control (●). IHL-305 (45 mg/kg) was administered on days 4, 8 and 12 (schedule A,▲), days 8, 12 and 16 (schedule B, ■) or days 12, 16
and 20 (schedule C, ♦), and the survival time was analyzed (n=5, each group).
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doxorubicin liposomes have been applied for ovarian can-
cer therapy. We demonstrated that IHL-305 was retained
within the ascites of the mice and prolonged the survival
period of the mice.
Ovarian cancers advance to peritoneal metastasis
through the dissemination of the cancer cells from the
ovary to the peritoneal cavity. In this study, we used a
clear cell type ovarian cancer cell line, ES-2 to establish
peritoneal metastasis models (Figure 1). We also examined
an adenocarcinoma ovarian cell line, SK-OV-3, and the
amount of vascular endothelial growth factor (VEGF) in
the spheroid culture supernatant was much higher for the
ES-2 cells than for the SK-OV-3 cells (data not shown).
VEGF reportedly plays an important role in the progres-
sion of peritoneal metastasis [28]. In clinical studies, clear
cell type ovarian cancer has exhibited a resistance to
chemotherapy [29]. Therefore, we selected ES-2 cells as
an aggressive peritoneal metastasis model in this study.
In general, peritoneal metastasis induced the accumu-
lation of ascites, including floating cancer cell aggre-
gates. We focused on the floating cells, which showed
anchorage-independent growth and were regarded as
comparable to the spheroids of cancer cells in the
in vitro peritoneal metastasis model. We detected the ac-
tivation of Akt in both the in vivo and the in vitro mod-
els of peritoneal metastasis (Figure 2). Akt reportedly
plays an important role in resistance to anoikis (detach-
ment-induced apoptosis) [23]. In addition, the activation
of EGFR was also detected in both models. However,
EGF, an activating ligand of EGFR, was not detected in
the spheroid culture medium or ascites (data not
shown). A three-dimensional culture resulting in the up-
regulation of HER2 has been reported [13]. Therefore,
alterations in the formation of three-dimensional struc-
tures might activate the EGFR pathways.Platinum and taxane agents are used as standard
chemotherapy for the treatment of ovarian cancers. We
examined the cytotoxic activity of CDDP, SN-38, PTX and
PD153035 against monolayer and spheroids of ES-2 cells.
Spheroids of ES-2 cells demonstrated resistance to the
agents tested, especially to CDDP and PTX, though these
agents exerted potent activity in monolayer cultures
(Figure 3A). Cancer cells bearing the B-raf gene mutation
have been reported to exhibit resistance to EGFR inhibi-
tors, and ES-2 cells carry this mutation [27]; therefore, we
assumed that the ES-2 cells were resistant to the EGFR
inhibitors. Targeting Akt is still remaining but among the
tested agents, SN-38 exerted the highest cytotoxic activity
(Figure 3B); thus, we applied CPT-11, a prodrug of SN-38,
for the treatment of the peritoneal metastasis.
Liposomal formulations improve the pharmacokinetic
profile, but the profile of IHL-305 in a peritoneal metas-
tasis model with ascites has not been previously exam-
ined. In the present study, a larger amount of IHL-305
was retained in the ascites, compared with CPT-11
(Figure 4B). Generally, therapeutic agents in the periton-
eal cavity are absorbed through vessels and lymph nodes.
High molecular weight agents are mainly absorbed
through lymph nodes, whereas low molecular weight
agents are mainly absorbed through vessels [30]. In peri-
toneal metastasis, cancer cells invading the lymph nodes
reduce the absorption by lymph nodes. The absorption
rate of IHL-305, a high molecular weight agent, has been
shown to be lower than that of CPT-11 (Figure 4B). It is
suggested, therefore, that those improved pharmacoki-
netic profile of IHL-305 leads to an enhancement of the
anti-cancer efficacy (Figure 5A). As shown in Table 1,
ascites fluids have observed in CPT-11 group on day 31,
whereas it has not observed on days 18 and 26. It was
thought that this dosage of CPT-11 was not enough to
cure the tumor cells completely, although this dosage
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remaining tumor cells in CPT-11-treated mouse prolifer-
ated and then release of the ascites fluids was induced.
Moreover, IHL-305 prolonged the survival time when
administered according to any of the schedules that were
examined (Figure 5B). IHL-305 was administered on day
12 after the inoculation of ES-2 cells; at this stage,
advanced tumor invasion (omentum, pancreas, etc.) was
apparent. Nevertheless, IHL-305 exhibited a therapeutic
efficacy against the invaded tumors in addition to the
cancer cell aggregates in the ascites.
Conclusion
We demonstrated that the activation of EGFR pathways
contributes to the aggressive progression observed in an
established ES-2 peritoneal metastasis model, and IHL-
305 effectively suppressed the progression of peritoneal
metastasis and prolonged the survival period in this
model. This liposomal formulation was considered as an
effective delivery tool toward peritoneal cavity.
Materials and methods
Reagents
CPT-11 and SN-38 were obtained from Yakult Honsha,
Co., Ltd. (Tokyo, Japan). IHL-305 was obtained from
Terumo Corporation (Tokyo, Japan). PTX and CDDP were
obtained from Sigma, Inc. (St. Louis, MO, USA). PD153035
was obtained from Merck KGaA (Darmstadt, Germany).
Cell cultures
The ES-2 cell line, a human ovarian clear cell carcinoma,
was obtained from American Type Culture Collection
(Manassas, VA, USA). For the spheroid cultures, the ES-
2 cells were seeded into a 96-well spheroid culture plate
(Sumilon cell tight Multiwell plate; Sumitomo Bakelite
Co., Ltd, Tokyo, Japan) on day 1 (2500 cells/well; 50 μL/
well). Cells were collected on days 4 and 7 and used for
the immunoblot analysis.
Immunoblot analysis of EGFR pathways
The harvested spheroid culture cells or cancer cells from
the peritoneal cavity were washed in ice-cold PBS and
lysed in RIPA buffer (10 mM Tris–HCl [pH7.4], 0.1%
nonidet-P-40, 0.1% sodium deoxycholate, 0.1% SDS, 150
mM NaCl, 1 mM EDTA, 10μg/mL aprotinin, and phos-
phatase inhibitor cocktail [Nacalai Tesque, Inc., Kyoto,
Japan]). An immunoblot analysis was performed using
the following antibodies: anti-EGFR (1005; Santa Cruz
Biotechnologies, Inc., California, CA, USA), anti-Akt1/2/
3 (H-136; Santa Cruz Biotechnologies), anti-ERK2 (C-14;
Santa Cruz Biotechnologies), anti-β-actin (N-21; Santa
Cruz Biotechnologies), anti-phospho-EGFR (Tyr1069; Cell
Signaling Technology [CST], Inc., Beverly, MA, USA),
anti-phospho-Akt(193 H12, Ser473; CST) and anti-phopho-p44/42 MAPK (Erk1/2) (D13.14.4E, Thr202/
Tyr204; CST). All the antibodies were used at a dilution
of 1:1000 except for p-MAPK and β-Actin, which were
used at a dilution of 1:2000. All other chemicals were of
the highest purity available.
Cytotoxicity of anti-cancer agents against monolayers
and spheroids of ES-2 cells
ES-2 cells were seeded into a 96-well plate for mono-
layers or spheroid culture on day 1 (2500 cells/well) and
exposed to anti-cancer agents for 48 h on days 2 to 4
(monolayers) or days 5 to 7 (spheroids). The number of
viable cells was determined after exposure using the
CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega Corporation, Madison, WI, USA).
Laboratory animals
Four-week-old female BALB/c nu/nu mice were
obtained from Japan SLC, Inc. (Hamamatsu, Japan). All
of the in vivo experimental protocols were approved by
the animal care committee of the Yakult Central Insti-
tute for Microbiological Research.
Therapeutic study of CPT-11 and IHL-305 in peritoneal
metastasis mouse model
The efficacy of CPT-11 and IHL-305 against peritoneal
metastasis was then evaluated after the inoculation of
ES-2 cells (2 × 105 cells/200 μL saline) into the periton-
eal cavity (day 1) and the random division of the mice
into test groups. CPT-11 (45 mg/kg/day) or IHL-305
(45 mg/kg/day) was administered via the tail vein on
days 4, 8 and 12. The status of peritoneal metastasis was
then evaluated on days 18, 26 and 31 by monitoring the
volume of ascites and tumor nodules in the omentum,
diaphragm, mesenterium and pancreas. The schedule
dependency of IHL-305 was also examined. IHL-305
(45 mg/kg/dose) was administered via the tail vein to the
mice on days 4, 8 and 12, days 8, 12 and 16, or days 12, 16
and 20. The survival time of the mice receiving the various
therapies were then compared.
Pharmacokinetic profiles of CPT-11 and IHL-305 in mice
with peritoneal metastasis
About 20 days after the inoculation of ES-2 cells (2 × 105
cells) into the peritoneal cavity, CPT-11 (45 mg/kg) or
IHL-305 (45 mg/kg) was administered via the tail vein
to mice exhibiting the macroscopic accumulation of as-
cites. Under anesthesia, blood and ascites were excised
at 0.5, 6, 24, 48 and 67 hours after administration.
The concentration of total CPT-11 (tCPT-11), released
CPT-11 from the liposome (rCPT-11), SN-38 and SN-38
glucuronide (SN-38G) were determined using high-
performance liquid chromatography (HPLC).
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The incidence of abnormal ascites and the survival time
were analyzed using the Kaplan-Meier method. Probabil-
ity values of less than 5% were considered significant.
Abbreviations
HB-EGF: Heparin-binding EGF-like growth factor; SDF-1α: Stromal cell-derived
factor 1alpha; VCAM-1: Vascular cell adhesion molecule-1; EGFR: Epidermal
growth factor receptor; EPR: Enhanced permeability and retention;
RES: Reticuloendothelial system; PEG: Polyethylene glycol; CPT-11: Irinotecan
hydrochloride; PTX: Paclitaxel; CDDP: Cisplatin; VEGF: Vascular endothelial
growth factor.
Competing interest
All authors are employment of Yakult Honsha Co., Ltd.
Authors’ contributions
AT directed this study. HK and AT participated in the acquisition, analysis and
interpretation of all data. AK and NK conducted pharmacokinetic analysis. TM
participated in the management of IHL-305 among provider. All authors read
and approved the final manuscript.
Acknowledgements
The authors thank Prof. Masatoshi Watanabe (Yokohama National University)
for suggesting the importance of cellular aggregates in ascites in peritoneal
metastasis and of spheroids as an in vitro model. The authors also thank Dr.
Kiyoshi Terada for helpful suggestions in the application of the liposomal
agent; Dr. Hiroshi Nagata for support in the statistical analysis; Safety
Research Laboratory in our institute for animal care; and Mr. Hiroshi Kodaira
for contract management in the test article.
Received: 30 March 2012 Accepted: 4 October 2012
Published: 10 October 2012
References
1. American Cancer Society: Cancer Facts & Figures 2010. Atlanta: American
Cancer Society; 2010.
2. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS: Predictive value
of symptoms for early detection of ovarian cancer. J Natl Cancer Inst
2010, 102:222–229.
3. Trimble CL, Kosary C, Trimble EL: Long-term survival and patterns of care
in woman with ovarian tumors of low malignant potential. Gynecol Oncol
2002, 86:34–37.
4. Fung MF, Bryson P, Johnston M, Charmbers A: Screening postmenopausal
women for ovarian cancer: a systematic review. J Obstet Gynaecol Can
2004, 26:717–728.
5. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland
LJ, Walker JL, Bunger RA: Intraperitoneal cisplatin and paclitaxel in ovarian
cancer. N Engl J Med 2006, 354:34–43.
6. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin
EW, Clarke-Pearson DL, Malviya VK, DuBeshter B: Intraperitoneal cisplatin
plus intravenous cyclophosphamide versus intravenous cisplatin plus
intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med
1996, 335:1950–1955.
7. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL,
Carson LF, Wadler S, Sickel J: Phase III trial of standard-dose
intravenous cisplatin plus paclitaxel versus moderately high-dose
carboplatin followed by intravenous paclitaxel and intraperitoneal
cisplatin in small-volume stage III ovarian carcinoma: an intergroup
study of the Gynecologic Oncology Group, Southwestern Oncology
Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001,
19:1001–1007.
8. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D: Health-related
quality of life during and after intraperitoneal versus intravenous
chemotherapy for optimally debulked ovarian cancer: a gynecologic
oncology group study. J Clin Oncol 2007, 25:437–443.
9. Piccart MJ, Bertelsen K, James K, Cassidy J, Manginol C, Simonsen E, Stuart G,
Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C,
Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M,
Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S: Randomized intergrouptrial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women
with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst
2000, 92:699–708.
10. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F: Involvement
of SDF-1α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial
ovarian carcinoma. Int J Cancer 2008, 122:91–99.
11. Yagi H, Yotsumoto F, Miyamoto S: Heparin-binding epidermal growth
factor-like growth factor promotes transcoelomic metastasis in ovarian
cancer through epithelial-mesenchymal transition. Mol Cancer Ther 2008,
7:3441–3451.
12. Slack-Davis KK, Atkins KA, Harrer C, Hershey ED, Conaway M: Vascular cell
adhesion molecule-1 is a regulator of ovarian cancer peritoneal
metastasis. Cancer Res 2009, 69:1469–1476.
13. Pickl M, Ries CH: Comparison of 3D and 2D tumor models reveals
enhanced HER2 activation in 3D associated with an increased response
to trastuzumab. Oncogene 2009, 28:461–468.
14. Laurent-Puig P, Lievre A, Blons H: Mutations and response to epidermal
growth factor receptor inhibitors. Clin Cancer Res 2009, 15:1133–1139.
15. Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A: Comparative in vivo
studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol
1998, 12:1035–1040.
16. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T,
Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW: Reduced
cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated
doxorubicin and cyclophosphamide compared with conventional
doxorubicin and cyclophosphamide in a randomized, multicenter trial of
metastatic breast cancer. J Clin Oncol 2001, 19:3439–3441.
17. Allen TM, Austin GA, Chonn A, Lin L, Lee KC: Uptake of liposomes by
cultured mouse bone marrow macrophages: influence of liposome
composition and size. Biochim Biophys Acta 1991, 1061:56–64.
18. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M,
Taguchi T, Ogawa O: Phase II study of CPT-11, a new Camptothecin
derivative, in metastatic colorectal cancer. CPT-11 gastrointestinal cancer
study group. J Clin Oncol 1993, 11:909–913.
19. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifiji N, Kudoh S, Negoro S,
Nishioka M, Nakagawa K, Takada M: A new derivative of Camptothecin for
the treatment of refractory or relapsed small-cell lung cancer. J Clin
Oncol 1992, 10:1225–1229.
20. Matsuzaki T, Takagi A, Furuta T, Ueno S, Kurita A, Nohara G, Kodaira H,
Sawada S, Hashimoto S: Antitumor activity of IHL-305, a novel pegylated
liposome containing irinotecan, in human xenograft models. Oncol Rep
2012, 27:189–197.
21. Shmeeda H, Tzemach D, Mak L, Gabizon A: Her2-targeted pegylated
liposomal doxorubicin: Retention of targetspecific binding and
cytotoxicity after in vivo passage. J Control Release 2009,
136:155–160.
22. Lin Y-Y, Chang C-H, Lu Y-C, Hwang J-J, Tseng Y-L, Lin W-J, Ting G,
Wang H-E: Evaluation of pharmacokinetics of 111In-labeled VNP-
PEGylated liposome after intraperitoneal and intravenous
administration in a tumor/ascites mouse model. Cancer Biother
Radiopharm 2009, 24:453–460.
23. Liau S-S, Jazag A, Ito K, Whang EE: Overexpression of HMGA1 promotes
anoikis resistance and constitutive Akt activation in pancreatic
adenocarcinoma cells. British J Cancer 2007, 96:993–1000.
24. McGuire WP, Hoskins WJ, Brady MF, Kugera PR, Partridge EE, Look KY,
Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin
compared with paclitaxel and cisplatin in patients with stage III and
stage IV ovarian cancer. N Engl J Med 1996, 334:1–6.
25. Takagi A, Watanabe M, Ishii Y, Morita J, Hirokawa Y, Matsuzaki T,
Shiraishi T: Three-dimensional cellular spheroid formation provides
human prostate tumor cell with tissue-like features. Anticancer Res
2007, 27:45–54.
26. Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S:
Improved therapeutic activity of folate-targeted liposomal doxorubicin
in folate receptor-expressing tumor models. Cancer Chemother Pharmacol
2009, 66:43–52.
27. Estep AL, Palmer C, McComick F, Rauen KA: Mutation analysis of BRAF,
MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
PLoS One 2007, 2:e1279.
28. Sako A, Kitayama J, Koyama H, Ueno H, Uchida K, Hamada H, Nagawa H:
Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can
Konishi et al. BMC Cancer 2012, 12:462 Page 9 of 9
http://www.biomedcentral.com/1471-2407/12/462effectively suppress peritoneal metastasis of gastric cancer. Cancer Res
2004, 64:3624–3628.
29. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M,
Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the
ovary. Cancer 2000, 88:2584–9.
30. Ballard BE: Biopharmaceutical considerations in subcutaneous and
intramuscular drug administration. J Pharm Sci 1968, 57:357–378.
doi:10.1186/1471-2407-12-462
Cite this article as: Konishi et al.: PEGylated liposome IHL-305 markedly
improved the survival of ovarian cancer peritoneal metastasis in mouse.
BMC Cancer 2012 12:462.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
